Portal vein thrombosis
Conditions
Interventions
Edoxaban 30 to 60 mg / day for 14 days
Sponsors
Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Clinically (histologically or imagewise) diagnosed as chronic liver disease. 2) Patients who have been confirmed to have thrombus in the portal vein, superior mesenteric vein, or / and splenic vein on the image. 3) The latest inspection value within 14 days before registration (same day as two weeks before the registration day is acceptable) satisfies all of the following. Hemoglobin 9.0 g / dl or more (male), 8.0 g / dl or more (female) Platelet count 50,000 / mm 3 or more Creatinine clearance 30 ml / min or more 4) Child-Pugh classification A or B. 5) Weight 40 kg or more. 6) About participation in the examination Informed consent is obtained from the patient himself.
Exclusion criteria
Exclusion criteria: 1. Child-Pugh classification C. 2. Endoscopic examination confirms the presence of lesions at risk of gastrointestinal bleeding (esophageal gastric varices, gastric / duodenal ulcers, gastric antral vascular dilation, etc.), and does not perform prophylactic treatment. 3. Have active malignancy. 4. Patients taking anticoagulant or / and antiplatelet drugs. 5. Patients with a history of clear bleeding symptoms such as cerebral haemorrhage. 6. Patients who weigh less than 40 kg at registration. 7. A woman who is pregnant or has a possibility of pregnancy, within 28 days after childbirth or breast-feeding. A man who wishes to become a partner's pregnant. 8. Mental illness or psychiatric symptoms are merged and it is judged that participation in the examination is difficult. 9. It has severe hypersensitivity to the ingredients of Edoxaban. 10. Because of drug allergy, neither CT nor MRI using a contrast agent can be performed. 11. Others, the doctor in charge determines that participation in this examination is inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction rate of portal vein thrombus 14 days after edoxaban administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of edoxaban administration against portal vein thrombosis | — |
Countries
Japan
Contacts
Public ContactHajime Takatori
Kanazawa University Hospital Gastroenterology
Outcome results
None listed